

Adam D Devore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4635712/publications.pdf>

Version: 2024-02-01

253
papers

10,330
citations

61945

43
h-index

43868

91
g-index

268
all docs

268
docs citations

268
times ranked

10309
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
2	Innovations in Heart Transplantation: A Review. <i>Journal of Cardiac Failure</i> , 2022, 28, 467-476.	0.7	9
3	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	3.0	77
4	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185.	1.4	3
5	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384.	0.7	16
6	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. <i>American Heart Journal</i> , 2022, 244, 135-148.	1.2	10
7	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
8	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. <i>American Heart Journal</i> , 2022, 245, 110-116.	1.2	3
9	Donation after circulatory death heart transplantation in the United States: An early report of donor characteristics. <i>JTCVS Techniques</i> , 2022, 12, 104-107.	0.2	16
10	Low Blood Pressure Threshold for Adverse Outcomes During Left Ventricular Assist Device Support. <i>American Journal of Cardiology</i> , 2022, 169, 78-85.	0.7	2
11	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines heart failure participating centers. <i>American Heart Journal</i> , 2022, 246, 1-11.	1.2	0
12	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 762-770.	2.9	8
13	Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121007973.	0.9	5
14	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
15	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. <i>Journal of Cardiac Failure</i> , 2022, 28, 1456-1463.	0.7	18
16	Health System Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	7
17	Poor Medication Adherence Is Associated With Worse Health Status In Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, S119.	0.7	0
18	The Future of heart procurement with donation after circulatory death: Current practice and opportunities for advancement. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1385-1390.	0.3	9

#	ARTICLE	IF	CITATIONS
19	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€HF. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3
20	Improving implementation of evidenceâ€based therapies for heart failure. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	2
21	Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1376-1381.	0.3	22
22	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 68-77.	3.0	12
23	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	1.2	8
24	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
25	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	1.6	27
26	Incorporating Patient Preferences Into Hospital Quality Metrics for Heart Failure. <i>JAMA Cardiology</i> , 2021, 6, 177.	3.0	2
27	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelinesâ€Heart Failure Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018696.	1.6	23
28	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
29	Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 327-337.	0.7	10
30	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heartâ€Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	1.9	28
31	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	1.6	24
32	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522.	3.0	62
33	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , 2021, 235, 82-96.	1.2	7
34	Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. <i>American Heart Journal</i> , 2021, 235, 149-157.	1.2	3
35	Association between sacubitril/valsartan initiation and realâ€world health status trajectories over 18â€months in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2670-2678.	1.4	7
36	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Can we prevent infections in patients with left ventricular assist devices?. European Journal of Heart Failure, 2021, 23, 1416-1418.	2.9	0
38	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Failure, 2021, 8, 2608-2616.	1.4	8
39	A Case for Re-Gifting. JACC: Case Reports, 2021, 3, 1010-1012.	0.3	0
40	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. Journal of Cardiac Failure, 2021, 27, 747-755.	0.7	3
41	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines® Heart Failure Hospitals. JAMA Cardiology, 2021, 6, 791.	3.0	14
42	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. JACC: Heart Failure, 2021, 9, 471-481.	1.9	38
43	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
44	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2021, 78, 330-343.	1.2	90
45	Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1589-1598.	0.3	12
46	EXPANDING the Donor Pool: Quantifying the Potential Impact of a Portable Organ-Care System for Expanded Criteria Heart Donation. Journal of Cardiac Failure, 2021, 27, 1462-1465.	0.7	10
47	Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. Circulation: Heart Failure, 2021, 14, e008236.	1.6	15
48	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. Journal of the American Heart Association, 2021, 10, e021276.	1.6	6
49	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. JACC: Heart Failure, 2021, 9, 28-38.	1.9	43
50	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008072.	0.9	2
51	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation: Heart Failure, 2021, 14, e008351.	1.6	10
52	HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an Epidemic. Journal of Cardiac Failure, 2021, , .	0.7	0
53	Trends in Cardiovascular Medicine: Update on Cardiac Transplantation. Trends in Cardiovascular Medicine, 2021, , .	2.3	0
54	A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction® Reply. JAMA - Journal of the American Medical Association, 2021, 326, 1977.	3.8	0

#	ARTICLE	IF	CITATIONS
55	Association of tacrolimus timeâ€toâ€therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. <i>Clinical Transplantation</i> , 2021, , e14542.	0.8	0
56	Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1345-1353.e2.	0.4	18
57	Increasing the United States heart transplant donor pool with donation after circulatory death. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e307-e309.	0.4	53
58	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	1.2	22
59	Quality and Outcomes in Heart Failure. , 2020, , 697-704.e2.		0
60	Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2020, 110, 567-574.	0.7	5
61	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines â€“ Heart Failure Program). <i>American Journal of Cardiology</i> , 2020, 125, 894-900.	0.7	15
62	Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 132-139.e1.	0.4	13
63	From Theory to Practice. <i>JACC: Heart Failure</i> , 2020, 8, 55-56.	1.9	1
64	Initiation of Angiotensin-Nepriylsin Inhibition After Acute Decompensated Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 202.	3.0	57
65	Stroke risk following implantation of current generation centrifugal flow left ventricular assist devices. <i>Journal of Cardiac Surgery</i> , 2020, 35, 383-389.	0.3	16
66	Angiotensin Receptor-Nepriylsin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1034-1048.	1.2	32
67	Angiotensin-Nepriylsin Inhibition in Black Americans. <i>JACC: Heart Failure</i> , 2020, 8, 859-866.	1.9	11
68	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	1.9	19
69	The Maximally Tolerated Dose. <i>JACC: Heart Failure</i> , 2020, 8, 739-741.	1.9	9
70	PROVIDE-HF primary results: Patient-Reported Outcomes in Vestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	1.2	8
71	Biomarkers in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006840.	1.6	3
72	Benefits of Optimizing Heart Failure Medication Dosage. <i>Journal for Nurse Practitioners</i> , 2020, 16, 498-503.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2020, 8, 1038-1049.	1.9	20
74	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	1.6	6
75	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 1349.	3.0	13
76	Reducing ECG Artifact From Left Ventricular Assist Device Electromagnetic Interference. <i>Journal of the American Heart Association</i> , 2020, 9, e017563.	1.6	11
77	Cardiac safety research consortium think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020, 230, 93-97.	1.2	14
78	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
79	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	1.6	2
80	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
81	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	1.2	7
82	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	1.9	44
83	Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. <i>Journal of Cardiac Failure</i> , 2020, 26, 635-636.	0.7	19
84	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006963.	1.6	13
85	The burden of noncardiac comorbidities and association with clinical outcomes in an acute heart failure trial: Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
86	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833.	1.6	25
87	Predictive initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. <i>American Heart Journal</i> , 2020, 223, 98-105.	1.2	12
88	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
89	Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e013047.	1.6	26
90	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Lawn Mower Versus Left Ventricular Assist Device. JACC: Case Reports, 2020, 2, 406-410.	0.3	1
92	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006645.	1.6	18
93	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	1.9	47
94	Reassessing Recipient Mortality Under the New Heart Allocation System. JACC: Heart Failure, 2020, 8, 548-556.	1.9	83
95	Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007094.	0.9	13
96	PROVIDER PERSPECTIVES ON THE FEASIBILITY AND UTILITY OF ROUTINE PATIENT-REPORTED OUTCOMES ASSESSMENT IN HEART FAILURE: A QUALITATIVE ANALYSIS. Journal of the American College of Cardiology, 2019, 73, 971.	1.2	0
97	Evolving the Hospital Readmissions Reduction Program. Journal of the American College of Cardiology, 2019, 74, 235-237.	1.2	2
98	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	5.5	207
99	Heart Failure Management Under Pressure. Journal of the American College of Cardiology, 2019, 73, 3064-3066.	1.2	0
100	Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	1.9	30
101	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. Journal of Cardiac Failure, 2019, 25, 1009-1011.	0.7	5
102	Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. ESC Heart Failure, 2019, 6, 1233-1242.	1.4	13
103	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Nephilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). American Journal of Cardiology, 2019, 124, 1900-1906.	0.7	19
104	The Future of Wearables in Heart Failure Patients. JACC: Heart Failure, 2019, 7, 922-932.	1.9	101
105	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. Circulation: Heart Failure, 2019, 12, e005171.	1.6	15
106	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. European Journal of Heart Failure, 2019, 21, 1472-1476.	2.9	2
107	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2019, 7, 933-941.	1.9	31
108	ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. JACC: Heart Failure, 2019, 7, 907-910.	1.9	2

#	ARTICLE	IF	CITATIONS
109	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, S151.	0.7	0
110	Influenza Vaccination in Patients With Heart Failure. <i>Circulation</i> , 2019, 139, 587-589.	1.6	3
111	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines [®] Heart Failure Registry. <i>American Heart Journal</i> , 2019, 211, 1-10.	1.2	17
112	Heart Failure With Preserved Ejection Fraction and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 602-611.	1.2	182
113	In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. <i>European Journal of Heart Failure</i> , 2019, 21, 1008-1011.	2.9	1
114	Heart Failure and Atrial Fibrillation, Like Fire and Fury. <i>JACC: Heart Failure</i> , 2019, 7, 447-456.	1.9	178
115	Association of Changes in Heart Failure Treatment With Patients' Health Status. <i>JACC: Heart Failure</i> , 2019, 7, 615-625.	1.9	20
116	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
117	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. <i>JACC: Heart Failure</i> , 2019, 7, 371-382.	1.9	36
118	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. <i>European Heart Journal</i> , 2019, 40, 3345-3352.	1.0	59
119	EFFECT OF SACUBITRIL/VALSARTAN INITIATION ON 30-DAY READMISSIONS AFTER A HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: A SECONDARY ANALYSIS OF THE PIONEER-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 901.	1.2	3
120	Clinical profiles in acute heart failure: an urgent need for a new approach. <i>ESC Heart Failure</i> , 2019, 6, 464-474.	1.4	42
121	EFFECT OF SACUBITRIL/VALSARTAN ON BIOMARKERS OF MYOCARDIAL STRESS IN PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE IN PIONEER-HF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 682.	1.2	1
122	RAAS Inhibition to Prevent GI Bleeding. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1779-1780.	1.2	0
123	Should Hepatitis C Donors Be Used in Na ⁺ -ve Urgent Status Patients on the Heart Transplant Waitlist?. <i>Current Transplantation Reports</i> , 2019, 6, 106-108.	0.9	0
124	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
125	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. <i>American Heart Journal</i> , 2019, 212, 101-112.	1.2	18
126	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19

#	ARTICLE	IF	CITATIONS
127	Target Doses of Heart Failure Medical Therapy and Blood Pressure. <i>JACC: Heart Failure</i> , 2019, 7, 350-358.	1.9	67
128	Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 408-417.	0.3	47
129	Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3176-3178.	1.2	4
130	A Case of Rare Inherited Restrictive Cardiomyopathy With Severe Biatrial Enlargement. <i>JACC: Case Reports</i> , 2019, 1, 588-591.	0.3	0
131	Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , 2019, 1, 273-279.	1.7	9
132	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e011560.	1.6	68
133	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	0.7	5
134	Angiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	13.9	848
135	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 85.	1.9	0
136	First-in-human experience with Aortix intraaortic pump. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 428-433.	0.7	29
137	Blood Pressure Response during Cardiopulmonary Exercise Testing in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 1345-1349.	0.2	3
138	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. <i>ASAIO Journal</i> , 2018, 64, 218-224.	0.9	13
139	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2018, 11, e004634.	1.6	20
140	Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668.	0.9	15
141	Timing of Postdischarge Follow-up and Medication Adherence Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
142	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 388-397.	1.9	21
143	Rationale and design of the comparison of sacubitril/valsartan versus enalapril on effect on natriuretic peptide response in patients stabilized from an acute heart failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	1.2	60
144	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. <i>American Heart Journal</i> , 2018, 200, 127-133.	1.2	13

#	ARTICLE	IF	CITATIONS
145	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
146	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
147	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
148	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 489.	3.0	37
149	Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?. <i>European Journal of Heart Failure</i> , 2018, 20, 723-724.	2.9	0
150	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	3.0	346
151	Decline of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2408-2409.	1.2	16
152	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529.	6.3	1,179
153	Cangrelor use prior to left ventricular assist device surgery: a case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 131-133.	1.0	8
154	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400.	1.6	36
155	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018, 39, 4255-4256.	1.0	54
156	Preventing Heart Failure in Diabetes. <i>JACC: Heart Failure</i> , 2018, 6, 831-832.	1.9	0
157	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines Heart Failure Registry. <i>JAMA Cardiology</i> , 2018, 3, 917.	3.0	50
158	Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 465-473.	1.9	65
159	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	1.6	134
160	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004729.	0.9	31
161	Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 698-700.	1.9	4
162	Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 351-366.	1.2	775

#	ARTICLE	IF	CITATIONS
163	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <sc>FIGHT</sc> trial. ESC Heart Failure, 2018, 5, 1035-1043.	1.4	25
164	Vaccination Trends in Patients With Heart Failure. JACC: Heart Failure, 2018, 6, 844-855.	1.9	30
165	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.	0.7	16
166	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. Clinical Cardiology, 2018, 41, 1259-1267.	0.7	10
167	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. Journal of the American Heart Association, 2018, 7, .	1.6	26
168	Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. Journal of Hospital Medicine, 2018, 13, 170-176.	0.7	3
169	The impact of a failing right heart in patients supported by intra-aortic balloon counterpulsation. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 709-718.	0.4	22
170	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. American Journal of Cardiology, 2017, 119, 886-892.	0.7	9
171	Can Vaccinations Improve Heart Failure Outcomes?. JACC: Heart Failure, 2017, 5, 194-203.	1.9	47
172	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <sc>RELAX</sc> trial. European Journal of Heart Failure, 2017, 19, 893-900.	2.9	123
173	Acute Heart Failure. JACC: Heart Failure, 2017, 5, 329-336.	1.9	29
174	Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	104
175	Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. Clinical Transplantation, 2017, 31, e12961.	0.8	1
176	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal, 2017, 189, 177-183.	1.2	43
177	Achieving a Maximally Tolerated β -Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	1.2	41
178	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 TF	0.9	15
179	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	1.9	11
180	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 483-493.	1.9	41

#	ARTICLE	IF	CITATIONS
181	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. <i>American Heart Journal</i> , 2017, 186, 130-138.	1.2	27
182	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 767.	1.2	0
183	THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 784.	1.2	0
184	A HOSPITAL LEVEL ANALYSIS OF 30-DAY READMISSION RATES FOR HEART FAILURE PATIENTS AND LONG-TERM SURVIVAL AMONG HIGHEST AND LOWEST PERFORMING HOSPITALS, FINDINGS FROM GET WITH THE GUIDELINES-HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2565.	1.2	0
185	ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 678.	1.2	3
186	Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) <i>Tj ETQq0 0 0 rgBT(Overlock40 Tf 50 5</i>	1.2	0
187	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 136.	3.0	50
188	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
189	The Risk of Stroke on Left Ventricular Assist Device Support. <i>JACC: Heart Failure</i> , 2017, 5, 712-714.	1.9	12
190	Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. <i>Circulation</i> , 2017, 136, 765-772.	1.6	27
191	Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. <i>Journal of Electrocardiology</i> , 2017, 50, 964-965.	0.4	1
192	Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. <i>ESC Heart Failure</i> , 2017, 4, 432-439.	1.4	56
193	Improving heart failure health: is there a secret Swedish sauce?. <i>European Journal of Heart Failure</i> , 2017, 19, 1117-1118.	2.9	0
194	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2017, 14, 434-443.	1.3	15
195	Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 663-671.	1.9	33
196	Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist. <i>JACC: Heart Failure</i> , 2017, 5, 621-631.	1.9	36
197	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2476-2486.	1.2	671
198	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23

#	ARTICLE	IF	CITATIONS
199	TCT-591 First-in-Human Experience with Aortix Intra-Aortic Pump. Journal of the American College of Cardiology, 2017, 70, B244-B245.	1.2	1
200	Liver function tests in patients with acute heart failure and associated outcomes: insights from <sc>ASCEND-HF</sc>. European Journal of Heart Failure, 2016, 18, 424-432.	2.9	45
201	Assessing Consequences of Intraaortic Balloon Counterpulsation Versus Left Ventricular Assist Devices at the Time of Heart Transplantation. ASAIO Journal, 2016, 62, 232-239.	0.9	19
202	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. JACC: Heart Failure, 2016, 4, 935-946.	1.9	68
203	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 781-788.	0.7	24
204	Timing and Causes of Readmission After Acute Heart Failure Hospitalization Insights From the Heart Failure Network Trials. Journal of Cardiac Failure, 2016, 22, 875-883.	0.7	78
205	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace, 2016, 18, 1135-1142.	0.7	31
206	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. American Heart Journal, 2016, 179, 99-106.	1.2	8
207	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. Journal of Cardiac Failure, 2016, 22, S27.	0.7	0
208	Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	0
209	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	1.2	14
210	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	127
211	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines Heart Failure registry. American Heart Journal, 2016, 182, 9-20.	1.2	115
212	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 757-766.	0.9	22
213	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure. JACC: Heart Failure, 2016, 4, 649-661.	1.9	16
214	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. American Journal of Cardiology, 2016, 117, 946-951.	0.7	23
215	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. Journal of Cardiac Failure, 2016, 22, 738-742.	0.7	23
216	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	0.7	47

#	ARTICLE	IF	CITATIONS
217	A Machine Without an Owner's Manual. JACC: Heart Failure, 2016, 4, 218-219.	1.9	3
218	Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?. Journal of the American College of Cardiology, 2016, 67, 963-972.	1.2	46
219	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	0.7	35
220	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	24
221	Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S36-44.	0.9	57
222	High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. Journal of Heart and Lung Transplantation, 2016, 35, 722-730.	0.3	28
223	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	1.2	28
224	Getting to a Man's Heart through His Colon. Texas Heart Institute Journal, 2016, 43, 168-170.	0.1	3
225	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. American Heart Journal, 2015, 170, 1124-1132.	1.2	8
226	Torsemide Versus Furosemide in Heart Failure Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 438-443.	0.8	28
227	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. Circulation: Heart Failure, 2015, 8, 741-748.	1.6	235
228	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. Circulation: Heart Failure, 2015, 8, 243-251.	1.6	20
229	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 97-107.	1.9	95
230	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2015, 17, 340-346.	2.9	22
231	Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure. Journal of Cardiac Failure, 2015, 21, S114-S115.	0.7	0
232	Measuring heart failure quality: does perfection matter?. Heart, 2015, 101, 1691-1692.	1.2	0
233	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	0.9	22
234	Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. Journal of Cardiac Failure, 2015, 21, 667-673.	0.7	20

#	ARTICLE	IF	CITATIONS
235	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	0.7	28
236	The Impact of Worsening Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 603-614.	1.0	30
237	What's Harder: Seeing a Doctor or Reducing Readmissions? —. <i>JACC: Heart Failure</i> , 2015, 3, 774-776.	1.9	0
238	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35
239	Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure. <i>Evidence-Based Medicine</i> , 2014, 19, 153-153.	0.6	1
240	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
241	Transient and persistent worsening renal function during hospitalization for acute heart failure. <i>American Heart Journal</i> , 2014, 168, 891-900.	1.2	36
242	Chest pain in patients with heart failure: why history may matter. <i>European Heart Journal</i> , 2014, 35, 3408-3409.	1.0	4
243	Techniques and applications of perioperative therapeutic plasma exchange. <i>Current Opinion in Anaesthesiology</i> , 2014, 27, 57-64.	0.9	18
244	Patient Selection for Advanced Heart Failure Therapy Referral. <i>Critical Pathways in Cardiology</i> , 2014, 13, 1-5.	0.2	17
245	Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing. <i>Journal of Cardiac Failure</i> , 2014, 20, S49-S50.	0.7	0
246	Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing. <i>American Journal of Cardiology</i> , 2014, 114, 1059-1064.	0.7	17
247	Medical Management of Patients With Continuous-Flow Left Ventricular Assist Devices. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 283.	0.4	27
248	Ascending Aorta to Main Pulmonary Artery Fistula Following Orthotopic Heart Transplantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, e25-e27.	1.1	0
249	VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. <i>Annals of Cardiothoracic Surgery</i> , 2014, 3, 603-5.	0.6	3
250	Response to Letter Regarding Article, "Selecting a Noninvasive Imaging Study After an Inconclusive Exercise Test". <i>Circulation</i> , 2011, 123, .	1.6	0
251	Predictors of Hypertension Control in a Diverse General Cardiology Practice. <i>Journal of Clinical Hypertension</i> , 2010, 12, 570-577.	1.0	18
252	Selecting a Noninvasive Imaging Study After an Inconclusive Exercise Test. <i>Circulation</i> , 2010, 122, 1514-1518.	1.6	18

#	ARTICLE	IF	CITATIONS
253	Embolism after Inferior Vena Cava Filter Mesh Fragmentation. Journal of Vascular and Interventional Radiology, 2010, 21, 1782-1784.	0.2	1